Revelation BIOSCIENCES, Inc. (REVB) intrinsic value & 10-year financials
Revelation BIOSCIENCES, Inc. (REVB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.49
- Market cap
- $301.1K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 534.8%
- Free cash flow (FY2025)
- —
REVB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.9M | -$23.95 | — | — | 624.2% |
| FY2024 | — | -$15.0M | -$87.68 | -$18.3M | — | 445.4% |
| FY2023 | — | -$120.3K | -$0.53 | — | — | — |
| FY2022 | — | -$10.8M | -$20.09 | — | — | — |
| FY2021 | — | -$2.1M | -$21.25 | -$857.6K | — | — |
| FY2020 | — | -$136.4K | — | — | — | — |
| FY2019 | — | -$3.6K | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
REVELATION BIOSCIENCES, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
REVELATION BIOSCIENCES, INC. has historically struggled to out-earn its cost of capital, averaging just 5.3% ROIC.
REVELATION BIOSCIENCES, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
REVELATION BIOSCIENCES, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.